Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-660-5p inhibitor
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Subcutaneous, Intravenous, Intramuscular, Intranasal, Buccal, Intradermal, Intrathecal, Intravitreal, Intratumoral, Intraperitoneal, Parenteral, Implant
01
Overview
miR-660-5p inhibitor is a synthetic oligonucleotide designed to specifically bind and inhibit the microRNA miR-660-5p. In breast cancer and other malignancies, miR-660-5p acts as an oncogenic microRNA (oncomiR) that is upregulated and promotes tumor progression, proliferation, migration, invasion, and angiogenesis. Preclinical studies have demonstrated that transfection with a miR-660-5p inhibitor significantly reduces cancer cell proliferation, migration, invasion, and angiogenesis, potentially by restoring the expression of its target genes such as TMEM41B, TFCP2, and TET2.
- Other names
- hsa-miR-660-5p inhibitorhsa-miR660-5p inhibitorhsa-miR 660-5p inhibitormiR-660 inhibitormiR660 inhibitormiR 660 inhibitormicroRNA-660-5p inhibitormicroRNA660-5p inhibitormicroRNA 660-5p inhibitor
02
Targets
miR-660-5p (microRNA-660-5p)
Beyond the preview
Go deeper on miR-660-5p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-660-5p inhibitor.